The US Food and Drug Administration on Friday approved a cutting-edge new treatment for a devastating rare genetic disease called spinal muscular atrophy. The treatment, Zolgensma, made by Novartis' AveXis unit, is a one-time therapy that works to treat the disease at the genetic level. That means the drug's effects should last a long time, though...